Amanda Marshburn, NP
Family · Richlands, NCNPI 1003362765
Payments from drug & device makers
Across 45 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$108
- GSK$85
- AstraZeneca$66
- Novo Nordisk$64
- Amgen$62
- Boehringer Ingelheim$50
- plus $327 from 12 others
What the payments were for
- Food & beverage$762100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 7 | $108 |
| GSK | 5 | $85 |
| AstraZeneca | 4 | $66 |
| Novo Nordisk | 4 | $64 |
| Amgen | 4 | $62 |
| Boehringer Ingelheim | 3 | $50 |
| Pfizer | 3 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Eisai Inc. | 2 | $40 |
| Merck | 2 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $30 |
| Medtronic | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| AbbVie | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
How this compares
$762 in reported general payments places this provider in the 65th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 162 | $115,818 |
| EliquisApixaban | 70 | $69,620 |
| OzempicSemaglutide | 46 | $50,561 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $49,946 |
| MyrbetriqMirabegron | 74 | $49,631 |
| MounjaroTirzepatide | 38 | $43,573 |
| RybelsusSemaglutide | 20 | $26,910 |
| RexultiBrexpiprazole | 15 | $22,060 |
| XareltoRivaroxaban | 24 | $20,573 |
| JanuviaSitagliptin Phosphate | 20 | $10,488 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $9,679 |
| Levemir FlexpenInsulin Detemir | 33 | $9,676 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $9,299 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $9,270 |
| BelsomraSuvorexant | 18 | $7,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $50 | $125,497182 claims |
| Novo NordiskOzempic, Rybelsus | $64 | $77,47166 claims |
| PfizerEliquis, Premarin | $50 | $73,60782 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $85 | $59,24689 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $49,63174 claims |
| Lilly USA, LLCMounjaro | $108 | $43,57338 claims |
| Johnson & JohnsonXarelto | $14 | $20,57324 claims |
| MerckJanuvia, Belsomra | $39 | $18,14538 claims |
| AbbVieSynthroid | $19 | $1,53625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,522 family providers in North Carolina.
Other family in Richlands
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.